133 related articles for article (PubMed ID: 21233302)
1. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Wu H; Ramanathan RK; Zamboni BA; Strychor S; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Maruca LJ; Bang YJ; Zamboni WC
J Clin Pharmacol; 2012 Feb; 52(2):180-94. PubMed ID: 21233302
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
Wu H; Ramanathan RK; Zamboni BA; Strychor S; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Maruca LJ; Bang YJ; Zamboni WC
Int J Nanomedicine; 2012; 7():5555-64. PubMed ID: 23112576
[TBL] [Abstract][Full Text] [Related]
3. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
Zamboni WC; Maruca LJ; Strychor S; Zamboni BA; Ramalingam S; Edwards RP; Kim J; Bang Y; Lee H; Friedland DM; Stoller RG; Belani CP; Ramanathan RK
J Liposome Res; 2011 Jun; 21(2):158-65. PubMed ID: 20626314
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Zamboni WC; Strychor S; Maruca L; Ramalingam S; Zamboni BA; Wu H; Friedland DM; Edwards RP; Stoller RG; Belani CP; Ramanathan RK
Clin Pharmacol Ther; 2009 Nov; 86(5):519-26. PubMed ID: 19675541
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
Zamboni WC; Ramalingam S; Friedland DM; Edwards RP; Stoller RG; Strychor S; Maruca L; Zamboni BA; Belani CP; Ramanathan RK
Clin Cancer Res; 2009 Feb; 15(4):1466-72. PubMed ID: 19190127
[TBL] [Abstract][Full Text] [Related]
6. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
Eur J Clin Pharmacol; 2013 Dec; 69(12):2073-81. PubMed ID: 23989300
[TBL] [Abstract][Full Text] [Related]
8. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.
Zamboni WC; Eiseman JL; Strychor S; Rice PM; Joseph E; Zamboni BA; Donnelly MK; Shurer J; Parise RA; Tonda ME; Yu NY; Basse PH
J Liposome Res; 2011 Mar; 21(1):70-80. PubMed ID: 20528623
[TBL] [Abstract][Full Text] [Related]
9. Allometric scaling of pegylated liposomal anticancer drugs.
Caron WP; Clewell H; Dedrick R; Ramanathan RK; Davis WL; Yu N; Tonda M; Schellens JH; Beijnen JH; Zamboni WC
J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):653-69. PubMed ID: 21863380
[TBL] [Abstract][Full Text] [Related]
10. STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.
Yu NY; Conway C; Pena RL; Chen JY
Anticancer Res; 2007; 27(4B):2541-5. PubMed ID: 17695551
[TBL] [Abstract][Full Text] [Related]
11. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
12. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.
Nekkanti V; Venkateswarlu V; Ansari KA; Pillai R
Curr Drug Deliv; 2011 Nov; 8(6):661-6. PubMed ID: 22313161
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.
Schmidt KT; Huitema ADR; Dorlo TPC; Peer CJ; Cordes LM; Sciuto L; Wroblewski S; Pommier Y; Madan RA; Thomas A; Figg WD
Cancer Chemother Pharmacol; 2020 Oct; 86(4):475-486. PubMed ID: 32897402
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Kirschbrown WP; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
Int J Nanomedicine; 2015; 10():1201-9. PubMed ID: 25709442
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.
Schell RF; Sidone BJ; Caron WP; Walsh MD; White TF; Zamboni BA; Ramanathan RK; Zamboni WC
Nanomedicine; 2014 Jan; 10(1):109-17. PubMed ID: 23891988
[TBL] [Abstract][Full Text] [Related]
16. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Joerger M; Hess D; Delmonte A; Gallerani E; Fasolo A; Gianni L; Cresta S; Barbieri P; Pace S; Sessa C
Br J Clin Pharmacol; 2015 Jul; 80(1):128-38. PubMed ID: 25580946
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Infante JR; Keedy VL; Jones SF; Zamboni WC; Chan E; Bendell JC; Lee W; Wu H; Ikeda S; Kodaira H; Rothenberg ML; Burris HA
Cancer Chemother Pharmacol; 2012 Nov; 70(5):699-705. PubMed ID: 22941375
[TBL] [Abstract][Full Text] [Related]
18. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M
Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Rowinsky EK; Rizzo J; Ochoa L; Takimoto CH; Forouzesh B; Schwartz G; Hammond LA; Patnaik A; Kwiatek J; Goetz A; Denis L; McGuire J; Tolcher AW
J Clin Oncol; 2003 Jan; 21(1):148-57. PubMed ID: 12506184
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
